Comparison of two tobramycin nebuliser solutions: Pharmacokinetic, efficacy and safety profiles of T100 and TNS

Journal of Cystic Fibrosis

Volumn 13, Issue 6, 2014, Pages 653-660

  Sands, Dorota ^a   Sapiejka, Ewa ^b   Gaszczyk, Grzegorz ^c   Mazurek, Henryk ^d  

^a INSTITUTE OF MOTHER AND CHILD   (Poland)

^b Oddzia Interny Dzieci   (Poland)

^c Centrum Pulmonologii I Alergologii   (Poland)

^d Klinika Pneumonologii i Mukowiscydozy IGiChP   (Poland)

Author keywords

Chronic pseudomonas aeruginosa infection; Cystic fibrosis; Inhalation time; Pharmacokinetics; Tobramycin nebuliser solution

Indexed keywords

TOBRAMYCIN; ANTIINFECTIVE AGENT;

ADD ON THERAPY; ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BRONCHOSPASM; CHILD; COLONY FORMING UNIT; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG SOLUTION; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INCIDENCE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MEDICAL NEBULIZER; MEDICATION COMPLIANCE; MULTICENTER STUDY; PLASMA CONCENTRATION-TIME CURVE; PSEUDOMONAS INFECTION; PURE TONE AUDIOMETRY; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION; TINNITUS; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; MICROBIOLOGY; NEBULIZER; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; THERAPEUTIC EQUIVALENCE; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CHILD; CROSS-OVER STUDIES; CYSTIC FIBROSIS; FEMALE; HUMANS; MALE; NEBULIZERS AND VAPORIZERS; PROSPECTIVE STUDIES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; THERAPEUTIC EQUIVALENCY; TOBRAMYCIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84911951803     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2014.04.006     Document Type: Article

References (11)

1. Ramsay B.W., Pepe M.S., Quan J.M., Otto K.L., Montgomery A.B., Williams-Warren J., et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999, 340:23-30.
2. Hagermann J.K., Hancock K.E., Klepser M.E. Aerosolised antibiotics: a critical appraisal of their use. Expert Opin Drug Deliv 2006, 3(1):71-86.
3. Miller M.R., Hankinson J., Brusasco V., Burgos F., Casaburi R., Coates A., et al. Standardisation of spirometry. Eur Respir J 2005, 26:319-338.
4. Griese M., Eismann C., Börner G., Denk O., Schierholz J.M., Keller M., et al. A pharmacokinetics and safety comparison of a highly concentrated tobramycin solution with TOBI. J Aerosol Med Pulm Drug Deliv 2013, 26(0):1-8. [Epub ahead of print].
5. Govoni M., Poli G., Cicerello H., Santoro D., Acerbi D., Ruzicka J. Pharmacokinetics of tobramycin nebulizer solution 300mg/4ml (Bramitob(r)) administered by Pari eFlow(r) rapid vs. Pari LC(r) Plus nebulizer in cystic fibrosis patients. Respir Drug Deliv 2012, 459-464.
6. Hubert D., Leroy S., Nove-Josserand R., Murris-Espin M., Mely L., Dominique S., et al. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow(r) rapid nebulizer in cystic fibrosis. J Cyst Fibros 2009, 8:332-337.
7. Geller D.E., Pitlick W.H., Nardella P.A., Tracewell W.G., Ramsey B.W. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002, 122:219-226.
8. Lenoir G., Antypkin Y.G., Miano A., Moretti P., Zanda M., Varoli G., et al. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Drugs 2007, 9(Suppl. 1):11-20.
9. Kearns G.L., Trang J.M. Introduction to pharmacokinetics: aminoglycosides in cystic fibrosis as a prototype. J Pediatr 1986, 108(2):847-853.
10. Horrevorts A.M., Degener J.E., Dzoljic-Danilovic G., Michel M.F., Kerrebijn K.F., Driessen O., et al. Pharmacokinetics of tobramycin in patients with cystic fibrosis. Implications for the dosing interval. Chest 1985, 88:260-264.
11. Konstan M.W., Flume P.A., Kappler M., Chiron R., Higgins M., Brockhaus F., et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J Cyst Fibros 2011, 10:54-61.